Analysis of the European Cancer Diagnostics Industry 2015-2020: Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Hospitals, Commercial Labs, POC Locations
Jun 25, 2015, 02:59 ET
DUBLIN, June 25, 2015 /PRNewswire/ --
Research and Markets (http://www.researchandmarkets.com/research/khpzsv/2015_market) has announced the addition of the "2015 Market Segmentation Analysis of the European Cancer Diagnostics Industry: Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Hospitals, Commercial Labs, POC Locations" report to their offering.
(Logo: http://photos.prnewswire.com/prnh/20130307/600769 )
A new study of the major business opportunities emerging in the European cancer diagnostics market during the next five years.
The report examines trends in the European market; reviews current and emerging assays; analyzes potential applications of new diagnostic technologies; forecasts sales of major tumor markers by country and market segment; profiles leading players and potential market entrants; and identifies specific business opportunities for suppliers.
The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the European cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field.
Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion.
European Market Overview
- Five-year test volume and sales projections by country.
- Comprehensive market segmentation analysis, including review of the market dynamics, structure, size, growth and major suppliers by country.
- Estimated universe of laboratories performing cancer diagnostic testing by country.
- Cancer statistics, etiology and recent developments in Europe.
Business Opportunities and Strategic Recommendations
- Specific new product development opportunities with potentially significant market appeal during the next five years.
- Design criteria for new products.
- Alternative market penetration strategies.
- Potential market entry barriers and risks.
Supplier Shares, Sales and Volume Forecasts
- Sales and market shares of major cancer diagnostic product
suppliers by individual test and country.
- Five-year test volume and sales forecasts for major tumor markers by country and market segment, including:
- Commercial/Private Laboratories
- Physician Offices/Group Practices
- Analysis of major molecular diagnostic and immunodignostic analyzers used for cancer testing, including their operating characteristics, features and selling prices.
- Assessment of latest technologies and their potential applications for cancer diagnostic testing.
- Review of competing/complementing technologies.
- Extensive listings of companies, universities and research centers developing new cancer diagnostic tests and detection technologies.
- Strategic assessments of major suppliers and start-up firms developing innovative cancer diagnostic technologies and products, including their sales, product portfolios, marketing tactics, collaborative arrangements, and new products in R&D.
- Agilent Technologies
- Becton Dickinson
- Biomedical Diagnostics
- Eiken Chemical
- Elitech Group
- Enzo Biochem
- Exact Sciences
- Guided Therapeutics
- Ortho-Clinical Diagnostics
- Panacea Pharmaceuticals
- Siemens Healthcare
- Takara Bio
- Targeted Diagnostics & Therapeutics
- Thermo Fisher
- Wako Pure Chemicals
For more information visit http://www.researchandmarkets.com/research/khpzsv/2015_market
Media Contact: Laura Wood , +353-1-481-1716, [email protected]
SOURCE Research and Markets
Share this article